My Best Weight

My Best Weight A NEW approach to managing weight - Our clinic provides evidence based medical management for those

03/06/2026

🧠 Could obesity medications influence addictive behaviours?

Many people taking GLP-1 medications have reported:

🍷 Drinking less alcohol
🚬 Smoking less
🤔 Experiencing fewer cravings

Now a major BMJ study involving more than 600,000 people with type 2 diabetes has found something intriguing.

Compared with another diabetes medication, GLP-1 medications were associated with:

⬇️ Lower risk of alcohol use disorder (HR 0.50)
⬇️ Lower risk of ni****ne use disorder (HR 0.72)
⬇️ Lower risk of opioid use disorder (HR 0.62)
⬇️ Lower risk of cannabis use disorder (HR 0.78)
⬇️ Lower risk of co***ne use disorder (HR 0.68)

And among people already living with a substance use disorder:

🏥 Fewer hospital visits
⚠️ Fewer overdoses
❤️ Lower substance-related mortality

But before anyone gets too excited…

⚠️ This was an observational study.

It cannot prove that GLP-1 medications prevent addiction and they should not be considered addiction treatments.

So why might these findings matter?

GLP-1 medications don’t just affect appetite. They also act on areas of the brain involved in reward, motivation and craving.

The most interesting message may be this:

🧠 Obesity is not about willpower.

And studies like this remind us that eating behaviours and addictive behaviours can both be influenced by complex brain pathways.

📚 Study: https://www.bmj.com/content/392/bmj-2025-086886

01/06/2026

“When I lose weight… I’ll be happier.”

It’s one of the most powerful promises society sells us.

And for many people, it feels intuitively true.

But the evidence suggests something more nuanced.

Obesity care can improve physical health, mobility, symptoms, metabolic health, confidence and quality of life. These benefits are real and they matter enormously.

But most obesity studies do not actually measure happiness itself.

They more commonly measure:
• Physical function
• Quality of life
• Symptoms
• Self-esteem
• Body image
• Depression and anxiety

These outcomes are important.

But they are not quite the same thing as lasting happiness.

Happiness is influenced by many other psychological, social and life factors and is not routinely measured in obesity trials.

For some people, a goal weight may represent more than a number on a scale.

It may represent a time in life that felt easier, happier, or when they felt more like themselves.

The challenge is that returning to a previous weight does not automatically return us to a previous life.

Life changes.

Relationships change.

Responsibilities change.

And humans adapt.

What once feels life-changing can, over time, become the new normal.

Psychologists sometimes refer to this as hedonic adaptation: our tendency to adjust to positive changes and gradually return to a familiar emotional baseline.

That doesn’t mean the benefits aren’t real.

It means that achieving a goal often brings a burst of satisfaction, while lasting wellbeing is shaped by many other factors, including relationships, purpose, autonomy and daily experiences.

Improved health can absolutely make these things easier to pursue.

Perhaps happiness comes less from weight loss itself…

And more from how improved health interacts with the broader realities of our lives.

Health matters.

Quality of life matters.

But happiness was never meant to be measured by a number on a scale.

What do you think?

23/05/2026

Maintaining weight loss & health is the real long-term challenge in obesity care - and SURMOUNT-MAINTAIN gives us important new evidence on how treatment dose matters.

Prof Carel le Roux, Co-founder of .ie , is a co-author on this major new study published in The Lancet.

At My Best Weight, our experts don’t just interpret the evidence — they help create it.

The study asked:

After 60 weeks of tirzepatide and substantial weight loss, what happens if treatment is continued, reduced, or stopped?

Participants were randomised to:

1️⃣ Continue maximum-dose tirzepatide
10mg or 15mg

2️⃣ Reduce to 5mg tirzepatide

3️⃣ Switch to placebo

📊 At 112 weeks, mean weight reduction was:

🔹 21.9%
with continued maximum-dose tirzepatide

🔹 16.6%
with 5mg tirzepatide

🔹 9.9%
after switching to placebo

But the key question was maintenance.

Participants maintained:

✅ 96.5% of prior weight loss
with maximum-dose tirzepatide

✅ 67.9%
with 5mg tirzepatide

⚠️ 42.8%
with placebo

Rescue therapy was offered if participants regained ≥50% of previous weight loss.

It was needed in:

⚠️ 67% of placebo participants

🔹 25% of the 5mg group

✅ 8% of those remaining on maximum-dose tirzepatide

Cardiometabolic improvements including blood pressure, lipids, HbA1c and waist circumference were also better maintained with ongoing treatment.

This matters because obesity is a chronic, relapsing disease.

The goal is not simply losing weight — it is maintaining long-term health improvement, safely and sustainably.

Follow the evidence, not Instagram.

21/05/2026

🚨 TRIUMPH-1: Retatrutide represents the next major leap in obesity medicine.

Eli Lilly has announced topline Phase 3 results from TRIUMPH-1 — a large global randomized trial of retatrutide, an investigational once-weekly “triple agonist” targeting GLP-1, GIP and glucagon receptors.

🧪 Trial design:
• 2,339 participants
• Adults with obesity or overweight + at least one weight-related complication
• Participants did NOT have diabetes
• Randomized to placebo or retatrutide 4 mg, 9 mg or 12 mg
• 80-week double-blind trial
• Pre-specified extension to 104 weeks in participants with BMI ≥35

📉 Weight loss results at 80 weeks:
🔹 4 mg: -19.0% (~47 lbs / 21.4 kg)
🔹 9 mg: -25.9% (~64 lbs / 29.2 kg)
🔹 12 mg: -28.3% (~70 lbs / 31.9 kg)

That degree of weight loss approaches levels traditionally associated with bariatric surgery.

Even more striking:
✅ 45.3% of participants on 12 mg lost ≥30% body weight
✅ 27.2% lost ≥35%
✅ 65.3% moved below the BMI threshold for obesity (BMI

17/05/2026

New evidence is changing how we think about long-term obesity care.

We are proud that Prof Carel le Roux, Co-founder of .ie , is an author on a new international study that may change how we think about long-term obesity treatment.

At My Best Weight, our clinical care is shaped by the latest science — and by experts who are not only interpreting the evidence, but helping to create it.

The ATTAIN-MAINTAIN study, just published in Nature Medicine, explored a clinically important question:

Can people who have already lost weight with injectable obesity medications maintain those benefits after switching to an oral GLP-1 treatment?

The study included people previously treated with tirzepatide or semaglutide, who were then randomised to once-daily oral orforglipron or placebo.

The results were striking:

In participants switching from tirzepatide to orforglipron, mean weight reduction was largely maintained — from 22.0% at the end of SURMOUNT-5 to 16.8% after 52 weeks of ATTAIN-MAINTAIN.

In participants switching from semaglutide to orforglipron, mean weight reduction was almost fully maintained — from 16.5% at the end of SURMOUNT-5 to 15.1% after 52 weeks of ATTAIN-MAINTAIN.

When analysed as maintenance of prior weight reduction, participants maintained an estimated 74.7% of previous weight reduction after tirzepatide and 79.3% after semaglutide with orforglipron — compared with 49.2% and 37.6% with placebo.

That contrast is important.

Stopping active treatment led to substantially more regain.

Switching to oral orforglipron helped preserve much more of the health gain already achieved.

Importantly, cardiometabolic improvements such as waist circumference, HbA1c, lipids and blood pressure were also broadly preserved, and the most common side effects were gastrointestinal, mostly mild to moderate.

This matters because obesity is a chronic, relapsing disease.

The goal is not just weight loss — it is long-term health improvement and maintenance.

World-leading obesity care means more than following trends.

Follow the evidence, not Facebook.

15/05/2026

Public conversation around obesity medications and “muscle loss” often lacks important nuance.

Across weight-loss interventions — including lifestyle change, bariatric surgery, and pharmacotherapy — some reduction in lean or ‘fat-free’ mass is expected as part of normal physiology.

In obesity medication trials, approximately 25–39% of total weight loss has been reported as “lean mass” on DEXA scans.

But this number is often misunderstood.

DEXA-derived “lean mass” does not equal skeletal muscle alone. It includes all non-fat, non-bone tissue — including total body water, glycogen-associated fluid, organ tissue, extracellular fluid, and changes in fat stored within tissues. This means DEXA may overestimate true functional muscle loss.

Emerging MRI data suggest skeletal muscle reductions may be more modest than headlines imply, while reductions in visceral fat, liver fat, and intramuscular fat may improve overall body composition and metabolic health.

Weight loss can also influence bone density through mechanical unloading and hormonal adaptation, but current evidence has not demonstrated a consistent increase in fracture risk directly attributable to these medications. Longer-term data remain important, particularly in higher-risk groups.

The real clinical question is not simply “Is some lean tissue lost?”

It’s:
How much of that reflects true skeletal muscle?
Is strength and physical function preserved?
And is treatment being paired with strategies that protect muscle and bone?

This is why evidence-based obesity care should include:
• Adequate protein intake
• Resistance training
• Physical activity
• Monitoring of functional health
• Personalised medical oversight

Obesity treatment should not be reduced to simplistic narratives.

The goal isn’t just weight reduction.

It’s improving metabolic health, reducing disease burden, preserving function, and helping people live healthier, stronger lives.

Follow the evidence… not Instagram.

03/05/2026

The podcast I did with The 2 Johnnies now has 300,000+ listens… and it is still regularly brought up by patients in clinic.

For many people, there is still a deeply ingrained perception that seeking medical support for obesity is somehow “taking the easy way out” or “cheating.”

Yet we rarely apply that same logic to treatment for other chronic diseases.

Obesity is still too often viewed through stigma, misunderstanding, and moral judgement rather than evidence-based medicine.

Sometimes the biggest barrier is not treatment itself… it’s perception.

This conversation clearly resonated with many people for a reason.

Follow the evidence… not stigma.

If you haven’t listened to the full episode, it’s well worth going over to Spotify to check it out.

28/04/2026

Missed doses. Delays. Holidays. Supply issues.

These practical issues are often not well addressed in guidelines or product literature — but in the real world, they matter.

How treatment is paused, continued, or restarted can influence tolerability, quality of life, and long-term treatment success.

This is where clinical experience, evidence-based prescribing, and expert medical support genuinely matter.

Obesity care is not just about writing a prescription or starting treatment.
It’s about safely navigating the real-world challenges that inevitably happen along the way.

Always speak to your own prescribing clinician before making changes to treatment.

25/04/2026

What is ‘Microdosing’ of GLP1-like medications?.

In medicine, we already use low doses.
It’s called titration. It’s evidence-based.

What’s being promoted online is often something else.

‘Microdosing’ 💉obesity medications sounds harmless

It makes prescription drugs feel like supplements —
low-risk, optional, casual.

But that’s not what this is.

In some cases, it’s diet culture —
repackaged in clinical language.

A medical veil over cosmetic weight loss.

Follow the evidence — not Instagram.

11/04/2026

Menopause & Weight Gain - hear Dr Caoimhe Hartley separating fact from fiction in collaboration with My Best Weight

It’s one of the most common concerns amongst women, but the science is often misunderstood.

Menopause itself isn’t the main driver of weight gain - but it does influence where fat is stored and how it impacts health.
That shift toward abdominal (visceral) fat is what matters most metabolically.

And HRT?
Despite the headlines, it’s largely weight neutral - but it may support body composition and symptoms that make weight management harder.

This is where nuance matters - focusing on weight alone misses the bigger picture.

👉 Health at midlife is about body composition, metabolic risk, and sustainable health behaviours - not just the number on the scale.

If excess weight is having a negative impact on health (this is how we now think of obesity - not just BMI and size) there are evidence-based treatments available.

Save this for later, and share with someone who needs a clearer understanding of what’s really going on.

Address

Unit 1, The Courtyard, 19 Castle Street
Dalkey
A96A8F8

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+35312546930

Website

Alerts

Be the first to know and let us send you an email when My Best Weight posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to My Best Weight:

Shortcuts

Share

Category